Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis

27Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the last few years, V-domain Ig-containing suppressor of T cell activation(VISTA) has been reported as a prognostic biomarker in articles including various solid tumours. However, their conclusions have been controversial. For this reason, we performed this meta-analysis to further verify the prognostic value of VISTA in solid tumours. All relevant literature was identified from PubMed, Embase, the Cochrane Library and Web of Science. Ten studies, including 2, 440 patients, were eligible for the analysis. The pooled results showed that high expression of VISTA was associated with favourable overall survival (OS) than that seen with low expression of VISTA (7 studies, hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66–0.86, P < 0.001). In addition, high expression of VISTA significantly correlated with high numbers of CD8 (+) tumour infiltrating lymphocytes (TILs) (3 studies, risk ratio (RR) = 1.80, 95% CI: 1.41–2.31, P < 0.001). In conclusion, these results indicate that VISTA is a potential prognostic biomarker in solid tumours.

Cite

CITATION STYLE

APA

He, X. L., Zhou, Y., Lu, H. Z., Li, Q. X., & Wang, Z. (2020). Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-59608-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free